Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 10/20 | 0.48 |
| ▸ | BTK | Q06187 | 6/20 | 0.48 |
| ▸ | JAK3 | P52333 | 4/20 | 0.48 |
| ▸ | ITK | Q08881 | 4/20 | 0.47 |
| ▸ | BRD4 | O60885 | 4/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 3/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | BRD2 | P25440 | 1/20 | 0.42 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.42 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL270179 | 0.84 | SYK (0.78) | SYKEGFRBTKJAK3ITK | |
| SCHEMBL270967 | 0.84 | SYK (0.58) | SYKEGFRBTKJAK3ITK | |
| SCHEMBL270239 | 0.82 | EGFR (0.58) | SYKEGFRBTKJAK3ITK | |
| SCHEMBL270436 | 0.82 | SYK (0.59) | SYKEGFRBTKITKBRD4 | |
| SCHEMBL270241 | 0.81 | BRD4 (0.61) | SYKEGFRBTKJAK3ITK | |
| SCHEMBL270775 | 0.81 | SYK (0.55) | SYKEGFRBTKJAK3ITK | |
| SCHEMBL270227 | 0.81 | EGFR (0.55) | SYKEGFRBTKJAK3ITK | |
| SCHEMBL270190 | 0.81 | EGFR (0.54) | SYKEGFRBTKJAK3ITK | |
| SCHEMBL270226 | 0.81 | EGFR (0.62) | SYKEGFRBTKJAK3ITK | |
| SCHEMBL271089 | 0.80 | EGFR (0.66) | SYKEGFRBTKJAK3ITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133900-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | TARGEGEN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | JAK2, TYK2, LTK | SYK 59/4885EGFR 335/4885BTK 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.